¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü

±³À°ÁÖÁ¦ : 2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462  

À̸ÞÀÏ : secretkda@thedementia.co.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 9 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï: ÀϹÝȸ¿ø 4¸¸¿ø, Á¤È¸¿ø 6¸¸¿ø, ºñȸ¿ø 11¸¸¿ø / ´çÀϵî·Ï: ÀϹÝȸ¿ø 5¸¸¿ø, Á¤È¸¿ø 7¸¸¿ø, ºñȸ¿ø 12¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 08:50~09:00 Opening Remarks À±¿µÃ¶(´ëÇÑÄ¡¸ÅÇÐȸÀå)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:00~09:20 Elecsys AD CSF biomarker best practice sharing of other countries Cristiano Tunesi(Roche Diagnostics International)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:20~09:40 Lecanemab in Early Alzheimer¡¯s Disease: Tau PET, Long-Term Outcomes, and Subcutaneous Formulation Michael Irizarry(Eisai)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:40~10:00 Baseline Characteristics Associated with Achieving Rapid Amyloid Plaque Clearance Following Donanemab Treatment Saygin Gonderten(Lilly)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 10:00~10:20 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 10:20~11:10 Monoclonal antibodies: how to apply the new hope in clinics ¾çµ¿¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 11:10~12:00 Insights into mechanisms of ARIA from preclinical models - 20 years of research Donna M. Wilcock(Indiana University)

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 12:00~13:00 ÃÑȸ ()

Åä·Ð 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 13:00~14:00 Poster Presentation ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:00~14:12 [±¸¿¬] Enhancement of glymphatic activity in early Alzheimer¡¯s disease using low-intensity ultrasound treatment ±èÀçÈ£(ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:12~14:24 [±¸¿¬] Evaluation of Efficacy and Safety of Low Dose Ionizing Radiation Therapy on Alzheimer¡¯s Disease: Interim Results of Multicenter Randomized, Single Blind, Phase II Clinical Trial Á¤¿ø±Ô(°­µ¿°æÈñ´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:24~14:36 [±¸¿¬] Effectiveness of personalized hippocampal network-targeted stimulation in Alzheimer¡¯s disease: A randomized controlled trial Á¤¿µÈñ(¸íÁöº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:36~14:48 [±¸¿¬] The Efficacy of a Home-Based, Augmented Reality Dual-Task Platform for Cognitive-Motor Training in Elderly Patients: A Pilot Observational Study À±º¸¶ó(°¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:48~15:00 [±¸¿¬] Presence of gait improvement 1 month after the CSF tap test in idiopathic normal pressure hydrocephalus ±è¹ÎÁÖ(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:00~15:10 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:10~15:30 Treatment-tailored cognitive change detection À̺´È­(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:30~15:50 Treatment-tailored ADL and behavioral change detection ¹é¹ÎÀç(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:50~16:10 Early neuropsychological parallel intervention: Process-based cognitive training on memory ½Å¹Î¿µ(¼­¿ï»ó´ã½É¸®´ëÇпø´ëÇб³)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:10~16:30 An area of superficial siderosis ÀåÇý¹Î(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:30~16:50 >4 microhemorrhages ¼­»ó¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:50~17:10 Anticoagulants and tPA ÀÓÀ缺(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:00~14:12 [±¸¿¬] TDP-43 Oligomers in Neurodegenerative diseases: AD and SD ¾È¼º¼ö(°¡Ãµ´ëÇб³)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:12~14:24 [±¸¿¬] Downregulation of Mest facilitate the progression of AD pathophysiology Á¶ÀÍÈÆ(¼­¿ï½Ã¸³´ë »ý¸í°úÇаú)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:24~14:36 [±¸¿¬] Identification of genetic risk loci and risk prediction for ¥â-amyloid deposition in East Asian population ±èÁØÇ¥(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:36~14:48 [±¸¿¬] Discordance Between Plasma AD Biomarkers and A¥â PET in Memory Clinic: Prevalence and Clinical Consequences À±Áöȯ(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:48~15:00 [±¸¿¬] White Matter Hyperintensities and Cholinergic Degeneration as Lewy Body Disease °­¼º¿ì(¼¼ºê¶õ½ºº´¿ø)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:00~15:10 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:10~15:30 Ä¡¸Å°ü¸®ÁÖÄ¡ÀÇ ½Ã¹ü»ç¾÷ ÃÖÈ£Áø(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:30~15:50 °æµµÀÎÁöÀå¾Ö ȯÀÚ°ü¸®¸¦ À§ÇÑ Á¤Ã¥ ¹æÇâ ¼­Áö¿ø(Áß¾ÓÄ¡¸Å¼¾ÅÍ)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:50~16:10 Áö¿ª »çȸ ÀÎÁö°Ç°­ÁõÁø Ãß±¸ Á¤Ã¥ ¾ç¿µ¼ø/ÇÏűæ(´ëÇÑÄ¡¸ÅÇÐȸ º¸ÇèÀÌ»ç/º¸°Çº¹ÁöºÎ ³ëÀΰǰ­°úÀå)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:10~16:30 Global phase3 trial of AR1001 in Early Alzheimer's Diseases: POLARIS-AD Á¤ÀçÁØ(¾Æ¸®¹ÙÀÌ¿À)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:30~16:50 KDS2010(Tisolagiline): A novel inhibitor of aberrant GABA production in reactive astrocytes for treatment of neurodegenerative diseases ±è»ó¿í(´º·Î¹ÙÀÌ¿ÀÁ¨)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:50~17:10 Double-blind, Placebo-controlled study of the effects of a live biotherapeutic product in preclincal Alzheimer's disease ÃÖ°­È£(Àü³²´ëº´¿ø)

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 17:10~17:30 Closing Remarks ¹× ½Ã»ó½Ä ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦40ȸ ´ëÇѽŰæ°úÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-04-21
´ÙÀ½±Û Á¦1Â÷ ±¹Á¦ÀÏÂ÷ÀÇ·áÇмú´ëȸ ¡¤ 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-04-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 5 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 8 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 10 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 6 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 7 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 10 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 5 2024-05-10
20642 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (4ÀÏÂ÷) : 2024-05-20 0 10 2024-05-10
20641 ¼­¿ï ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2024 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2024-05-19 0 11 2024-05-10
20640 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇаúÀÇ»çȸ Stanley Lam ¿öÅ©¼¥ : 2024-05-19 0 29 2024-05-10
20639 ¼­¿ï Á¦40ȸ ´ëÇѳëÀÎÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 14 2024-05-10
20638 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2024³âµµ ¿¬¼ö°­Á : 2024-05-18 0 9 2024-05-10
20637 ÀÎõ 2024³âµµ Á¦47Â÷ ´ëÇѺ¹ºÎ¿µ»óÀÇÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-18 0 7 2024-05-10
20636 Àü³² 2024 Á¦2Â÷ ´ëÇѾȰúÀÇ»çȸ ½ÉÆ÷Áö¿ò : 2024-05-18 0 1 2024-05-10
20635 ¼­¿ï ´ëÇÑÇǺκ´¸®ÇÐȸ Á¦22ȸ ÇǺκ´¸® ½ÉÆ÷Áö¿ò : 2024-05-18 0 26 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷